

Ni(II)/BINOL-Catalyzed Alkenylation of Unactivated C(sp³)-H Bonds

Yue-Jin Liu,^[a] Zhuo-Zhuo Zhang,^[a] Sheng-Yi Yan,^[a] Yan-Hua Liu^[a] and Bing-Feng Shi^{*[a,b]}

^[a]Department of Chemistry, Zhejiang University, Hangzhou 310027, China

^[b]State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, CAS, Shanghai 200032, China

Supporting Information

Table of Contents:

1. General information	S2
2. Experimental Section	S3
2.1 Optimization of Reaction Conditions	S3
2.2 General Procedure for the Alkenylation	S8
2.3 Sequential C-H Bonds Functionalization of Product	S24
2.4 Transformation of Product	S26
3. References	S27
4. References	S27


1. General Information

Anhydrous dimethyl sulfoxide, Ni(acac)₂, BINOL and Li₂CO₃ were purchased from Adamas-beta[®] and Aladdin[®] without additional purification. KTFA was obtained from Aldrich[®]. The other materials and solvents were purchased from Aladdin and other commercial suppliers and used without additional purification. NMR spectra were recorded on a Bruke Avance operating for ¹H NMR at 400 MHz and ¹³C NMR at 100 MHz, using TMS as internal standard. The peaks were internally referenced to TMS (0.00 ppm) or residual undeuterated solvent signal (77.16 ppm for ¹³C NMR). The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, m = multiplet, b = broad. Mass spectroscopy data of the products were collected on an HRMS-TOF instrument or a low-resolution MS instrument using EI ionization and ESI ionization.

2. Experimental Section


2.1 Optimization of Reaction Conditions

Screening of Solvents

			
Entry ^a	Solvent	Yield ^b	
		3a	3a'
1	DMF	17%	N.D.
2	DMSO	23%	N.D.
3	1,4-dioxane	trace	N.D.
4	Toluene	trace	N.D.
5	Pivalonitrile	15%	N.D.
6	DCE	trace	N.D.
7	NMP	23%	N.D.

^a The reactions were carried out **1a** (0.1 mmol), **2a** (0.2 mmol), Ni(acac)₂ (0.01 mmol), BDMAE (0.02 mmol), Na₂CO₃ (0.2 mmol), solvent (1 mL), N₂, 140 °C. ^b Yield of ¹H NMR. N.D. = No Detection.


Screening of Ni Salts



Entry ^a	Ni (10%)	Yield ^b of 3a
1	Ni(OTf) ₂	N.D.
2	NiCp ₂	trace
3	NiBr ₂	N.D.
4	NiCl ₂	trace
5	(dppe)NiCl ₂	10%
6	(dppp)NiCl ₂	18%
7	(PPh ₃) ₂ NiCl ₂	8%
8	Ni(acac) ₂	23%
9	(DME)NiCl ₂	N.D.

^a The reactions were carried out **1a** (0.1 mmol), **2a** (0.2 mmol), [Ni] (0.01 mmol), BDMAE (0.02 mmol), Na₂CO₃ (0.2 mmol), DMSO (1 mL), N₂, 140 °C. ^b Yield of ¹H NMR. N.D. = No Detection.


Screening of Bases




Entry ^a	Bases (2.0 eq.)	Yield ^b of 3a
1	Li_2CO_3	11%
2	Na_2CO_3	23%
3	K_2CO_3	8%
4	Cs_2CO_3	7%
5	NaHCO_3	8%
6	KHCO_3	12%
7	NaOAc	10%
8	NaTFA	22%
9	KTFA	25%
10	NaOTf	N.D.

^a The reactions were carried out **1a** (0.1 mmol), **2a** (0.2 mmol), $\text{Ni}(\text{acac})_2$ (0.01 mmol), BDMAE (0.02 mmol), base (0.2 mmol), DMSO (1 mL), N_2 , 140 °C. ^b Yield of ^1H NMR. N.D. = No detection.


Screening of Ligands




Entry ^a	L (20%)	Yield ^b of 3a	Entry ^a	L (20%)	Yield ^b of 3a
1	BINAP	10%	7	XPhos	13%
2	PPh ₃	9%	8	BDMAE	26%
3	DPPM	15%	9	DME	25%
4	DPPE	17%	10	TMEDA	17%
5	DPPB	13%	11	1,10-Phen	trace
6	DPPF	12%	12	BPy	trace




L13 24%




L14 38%




L15 34%




L16 48%




L17 73%



L18 43%




L19 63%



L20 58%

^a The reactions were carried out **1a** (0.1 mmol), **2a** (0.2 mmol), Ni(acac)₂ (0.01 mmol), Ligands (0.02 mmol), KTFA (0.2 mmol), DMSO (1 mL), N₂, 140 °C. ^b Yield of ¹H NMR. N.D. = No Detection.

Screening of Additives




Entry ^a	Additives (2.0 eq.)	Yield ^b of 3a
1	Li ₂ CO ₃	78% ^c
2	Na ₂ CO ₃	35%
3	K ₂ CO ₃	37%
4	NaHCO ₃	23%
5	KHCO ₃	21%
6	K ₃ PO ₄	8%
7	K ₂ HPO ₄	58%


^a The reactions were carried out **1a** (0.1 mmol), **2a** (0.2 mmol), Ni(acac)₂ (0.01 mmol), BINOL (0.02 mmol), KTFA (0.2 mmol), Additives (2.0 eq.), DMSO (1 mL), N₂, 140°C. ^b Yield of ¹H NMR.

^c Isolated yield. N.D. = No detection.

2.2 General Procedure for the Alkynylation




Condition : To an oven-dried 50 mL screw-capped vial was added substrate **1** (0.1 mmol, 1.0 eq.), **2** (0.2 mmol, 2.0 eq.), Ni(acac)₂ (0.002 mmol, 0.1 eq.), Li₂CO₃ (0.2 mmol, 2.0 eq.), potassium trifluoroacetate (0.2 mmol, 2.0 eq.), in DMSO (1.0 mL). The mixture was stirred for 10 h at 140 °C under N₂ followed by cooling. The resulting mixture was added water (3 mL), then extracted with EtOAc (10 mL) for three times. The combined organic phase washed with brine (10 mL) for three times and concentrated in *vacuo*. The residue was purified by preparative TLC using hexane/EtOAc = 20:1 as the eluent to afford the product.




1-cinnamyl-N-(quinolin-8-yl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.29 (br, 1H), 8.83 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.70 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.14 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.56-7.48 (m, 2H), 7.41 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.24-7.11 (m, 5H), 6.42 (d, *J* = 15.6 Hz, 1H), 6.26-6.18 (m, 1H), 2.57 (d, *J* = 7.6 Hz, 2H), 2.30-2.24 (m, 2H), 1.73-1.69 (m, 2H), 1.63-1.56 (m, 5H), 1.41-1.37 (m, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.07, 148.38, 139.00, 137.60, 136.35, 134.77, 133.37, 128.44, 128.10, 127.60, 127.12, 126.34, 125.66, 121.62, 121.35, 116.53, 48.75, 44.04, 34.34, 26.10, 23.16; **HRMS** (EI-TOF) calcd for C₂₅H₂₆N₂O (M⁺): 370.2045, found: 370.2047.




(E)-N-(quinolin-8-yl)-1-(3-(p-tolyl)allyl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.29 (br, 1H), 8.83 (d, *J* = 7.2 Hz, 1H), 8.71 (dd, *J* = 7.6, 0.8 Hz, 1H), 8.14 (d, *J* = 8.4 Hz, 1H), 7.56-7.47 (m, 2H), 7.41 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.13 (d, *J* = 8.0 Hz, 2H), 6.99 (d, *J* = 7.6 Hz, 2H), 6.39 (d, *J* = 15.6 Hz, 1H), 6.20-6.12 (m, 1H), 2.56 (d, *J* = 7.6 Hz, 2H), 2.30-2.20 (m, 5H), 1.70-1.68 (m, 2H), 1.60-1.58 (m, 5H), 1.41-1.38 (m, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.14, 148.36, 138.99, 136.83, 136.34, 134.81, 133.19, 129.13, 128.08, 127.58, 126.39, 126.22, 124.55, 121.59, 121.32, 116.50, 48.73, 44.03, 34.29, 26.09, 23.15, 21.24; **HRMS (EI-TOF)** calcd for C₂₆H₂₈N₂O (M⁺): 384.2202, found: 384.2205.




(E)-1-(3-(4-(tert-butyl)phenyl)allyl)-N-(quinolin-8-yl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.29 (br, 1H), 8.83 (d, *J* = 7.6 Hz, 1H), 8.69 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.13 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.56-7.42 (m, 2H), 7.40 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.22-7.16 (m, 4H), 6.40 (d, *J* = 15.6 Hz, 1H), 6.22-6.14 (m, 1H), 2.56 (d, *J* = 7.6 Hz, 2H), 2.28-2.22 (m, 2H), 1.70-1.67 (m, 2H), 1.63-1.58 (m, 5H), 1.42-1.34 (m, 1H), 1.27 (s, 9H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.17, 150.15, 148.35, 139.00, 136.33, 134.83, 134.78, 133.11, 128.08, 127.59, 126.03, 125.35, 124.79, 121.58, 121.32, 116.52, 48.76, 44.01, 34.59, 34.26, 31.42, 26.10, 23.15; **HRMS (EI-TOF)** calcd for C₂₉H₃₄N₂O (M⁺): 426.2671, found: 426.2672.




(E)-1-(3-(4-fluorophenyl)allyl)-N-(quinolin-8-yl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.28 (br, 1H), 8.82 (d, *J* = 7.6 Hz, 1H), 8.70 (d, *J* = 4.0 Hz, 1H), 8.14 (d, *J* = 8.4 Hz, 1H), 7.56-7.48 (m, 2H), 7.42 (dd, *J* = 8.4, 4.0 Hz, 1H), 7.18-7.14 (m, 2H), 6.85 (t, *J* = 8.4 Hz, 2H), 6.37 (d, *J* = 15.6 Hz, 1H), 6.16-6.09 (m, 1H), 2.55 (d, *J* = 7.6 Hz, 2H), 2.29-2.26 (m, 2H), 1.71-1.68 (m, 2H), 1.60-1.54 (m, 5H), 1.39 (s, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 174.95, 162.09 (d, *J* = 244.4 Hz), 148.35, 138.97, 136.39, 134.71, 133.75 (d, *J* = 3.2 Hz), 132.12, 128.09, 127.70, 127.68 (d, *J* = 18.1 Hz), 125.41 (d, *J* = 1.9 Hz), 121.51 (d, *J* = 24.8 Hz), 116.53, 115.35, 115.13, 48.78, 44.00, 34.39, 26.09, 23.16; **HRMS** (EI-TOF) calcd for C₂₅H₂₅FN₂O (M⁺): 388.1951, found: 388.1952.




(E)-1-(3-(3-methoxyphenyl)allyl)-N-(quinolin-8-yl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.29 (br, 1H), 8.83 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.70 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.13 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.56-7.47 (m, 2H), 7.40 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.09 (t, *J* = 8.0 Hz, 1H), 6.83 (d, *J* = 7.6 Hz, 1H), 6.73 (s, 1H), 6.68 (dd, *J* = 8.0, 1.6 Hz, 1H), 6.39 (d, *J* = 15.6 Hz, 1H), 6.25-6.17 (m, 1H), 3.66 (s, 3H), 2.57 (d, *J* = 7.6 Hz, 2H), 2.30-2.21 (m, 2H), 1.71-1.68 (m, 2H), 1.63-1.58 (m, 5H), 1.46-1.33 (m, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.02, 159.75, 148.40, 139.05, 138.97, 136.31, 134.72, 133.27, 129.38, 128.06, 127.56, 126.00, 121.60, 121.35, 119.02, 116.51, 112.90, 111.53, 55.19, 48.76, 43.98, 34.31, 26.08, 23.15; **HRMS** (EI-TOF) calcd for C₂₆H₂₈N₂O₂ (M⁺): 400.2151, found: 400.2154.




(E)-1-(3-(3-cyanophenyl)allyl)-N-(quinolin-8-yl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.27 (br, 1H), 8.81 (d, *J* = 7.6 Hz, 1H), 8.72 (d, *J* = 4.0 Hz, 1H), 8.15 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.57-7.49 (m, 2H), 7.45-7.37 (m, 4H), 7.24 (t, *J* = 8.0, 1H), 6.39-6.28 (m, 2H), 2.57 (d, *J* = 6.8 Hz, 2H), 2.35-2.28 (m, 2H), 1.80-1.69 (m, 2H), 1.65-1.54 (m, 5H), 1.46-1.36 (m, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 174.57, 148.45, 138.88, 138.72, 136.46, 134.52, 131.16, 130.49, 130.35, 129.64, 129.17, 128.85, 128.09, 127.57, 121.76, 121.56, 118.90, 116.56, 112.58, 48.90, 44.02, 34.47, 26.05, 23.15; **HRMS** (ESI-TOF) calcd for C₂₆H₂₆N₃O (M+H)⁺: 396.2070, found: 396.2088.




(E)-1-(3-(3-chlorophenyl)allyl)-N-(quinolin-8-yl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.28 (br, 1H), 8.81 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.71 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.13 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.56-7.48 (m, 2H), 7.41 (dd, *J* = 8.4, 4.0 Hz, 1H), 7.18 (s, 1H), 7.09-7.05 (m, 3H), 6.34 (d, *J* = 15.6 Hz, 1H), 6.28-6.20 (m, 1H), 2.55 (d, *J* = 7.2 Hz, 2H), 2.31-2.27 (m, 2H), 1.78-1.69 (m, 2H), 1.60-1.54 (m, 5H), 1.46-1.34 (m, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 174.80, 148.46, 139.44, 138.94, 136.37, 134.63, 134.36, 132.07, 129.61, 128.09, 127.55, 127.36, 127.04, 126.13, 124.60, 121.67, 121.45, 116.55, 48.81, 44.00, 34.42, 26.07, 23.16; **HRMS** (ESI-TOF) calcd for C₂₅H₂₆ClN₂O (M+H)⁺: 405.1728, found: 405.1741.




(E)-N-(quinolin-8-yl)-1-(3-(o-tolyl)allyl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.30 (br, 1H), 8.83 (d, *J* = 7.6 Hz, 1H), 8.72 (d, *J* = 4.0 Hz, 1H), 8.13 (d, *J* = 8.4 Hz, 1H), 7.55-7.47 (m, 2H), 7.41 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.30 (d, *J* = 7.6 Hz, 1H), 7.06-6.97 (m, 3H), 6.60 (d, *J* = 15.6 Hz, 1H), 6.12-6.04 (m, 1H), 2.60 (d, *J* = 7.6 Hz, 2H), 2.31-2.22 (m, 2H), 2.13 (s, 3H), 1.79-1.70 (m, 2H), 1.66-1.58 (m, 5H), 1.47-1.34 (m, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.02, 148.35, 138.99, 136.88, 136.35, 135.13, 134.74, 131.47, 130.05, 128.08, 127.58, 127.06, 126.97, 126.08, 125.95, 121.61, 121.32, 116.52, 48.84, 44.32, 34.36, 26.13, 23.16, 19.74; **HRMS** (ESI-TOF) calcd for C₂₆H₂₉N₂O (M+H)⁺: 385.2274, found: 385.2273.




(E)-1-(3-(2-chlorophenyl)allyl)-N-(quinolin-8-yl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.30 (br, 1H), 8.83 (d, *J* = 7.6 Hz, 1H), 8.72 (dd, *J* = 8.4, 1.6 Hz, 1H), 8.15 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.56-7.48 (m, 2H), 7.42 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.38 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.24 (dd, *J* = 7.6, 1.2 Hz, 1H), 7.08-7.01 (m, 2H), 6.79 (d, *J* = 15.6 Hz, 1H), 6.23-6.15 (m, 1H), 2.62 (d, *J* = 7.6 Hz, 2H), 2.31-2.24 (m, 2H), 1.72-1.69 (m, 2H), 1.64-1.57 (m, 5H), 1.45-1.37 (m, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 174.88, 148.36, 139.01, 136.39, 135.75, 134.70, 132.72, 129.64, 129.51, 128.73, 128.16, 128.09, 127.60, 127.25, 126.71, 121.63, 121.40, 116.59, 48.70, 44.12, 34.41, 26.09, 23.13; **HRMS** (ESI-TOF) calcd for C₂₅H₂₆ClN₂O (M+H)⁺: 405.1728, found: 405.1723.




(E)-1-(3-(naphthalen-2-yl)allyl)-N-(quinolin-8-yl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.32 (br, 1H), 8.85 (d, *J* = 7.2 Hz, 1H), 8.65 (d, *J* = 4.0 Hz, 1H), 8.09 (d, *J* = 8.0 Hz, 1H), 7.72-7.32 (m, 10H), 6.57 (d, *J* = 16.0 Hz, 1H), 6.39-6.31 (m, 1H), 2.62 (d, *J* = 7.6 Hz, 2H), 2.34-2.24 (m, 2H), 1.73-1.60 (m, 6H), 1.41-1.33 (m, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.03, 148.37, 138.97, 136.30, 135.06, 134.75, 133.66, 133.47, 132.84, 128.07, 127.96, 127.67, 127.57, 126.14, 125.74, 125.62, 123.94, 121.56, 121.37, 116.53, 48.87, 44.20, 34.40, 26.11, 23.19; **HRMS** (ESI-TOF) calcd for C₂₉H₂₉N₂O (M+H)⁺: 421.2274, found: 421.2285.




(E)-N-(quinolin-8-yl)-1-(3-(4-(trifluoromethyl)phenyl)allyl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.28 (br, 1H), 8.81 (d, *J* = 7.6 Hz, 1H), 8.67 (d, *J* = 4.0, 1.6 Hz, 1H), 8.13 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.56-7.48 (m, 2H), 7.42-7.38 (m, 3H), 7.26 (d, *J* = 7.2 Hz, 2H), 6.42 (d, *J* = 15.6 Hz, 1H), 6.36-6.28 (m, 1H), 2.58 (d, *J* = 7.2 Hz, 2H), 2.32-2.28 (m, 2H), 1.79-1.69 (m, 2H), 1.65-1.55 (m, 5H), 1.47-1.34 (s, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 174.73, 148.34, 140.99, 138.93, 136.40, 134.61, 132.05, 128.67, 128.09, 127.58, 126.37, 125.34 (q, *J* = 3.8), 121.66, 121.48, 116.56, 48.90, 44.07, 34.44, 26.07, 23.16; **HRMS** (ESI-TOF) calcd for C₂₆H₂₆F₃N₂O (M+H)⁺: 439.1992, found: 439.1996.




(E)-1-(3-(3-bromophenyl)allyl)-N-(quinolin-8-yl)cyclohexanecarboxamide

¹H NMR (400 MHz, CDCl₃) δ 10.27 (br, 1H), 8.81 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.72 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.14 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.56-7.48 (m, 2H), 7.42 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.33 (s, 1H), 7.24 (d, *J* = 8.0 Hz, 1H), 7.11-7.00 (m, 2H), 6.33 (d, *J* = 15.6 Hz, 1H), 6.27-6.20 (m, 1H), 2.56 (d, *J* = 6.7 Hz, 2H), 2.31-2.27 (m, 2H), 1.77-1.66 (m, 2H), 1.63-1.56 (m, 5H), 1.43-1.35 (m, 1H); **¹³C NMR (100 MHz, CDCl₃)** δ 174.80, 148.49, 139.73, 138.94, 136.38, 134.64, 131.98, 129.97, 129.91, 129.06, 128.09, 127.56, 127.43, 125.04, 122.66, 121.69, 121.46, 116.55, 48.85, 44.01, 34.42, 26.08, 23.17; **HRMS** (ESI-TOF) calcd for C₂₅H₂₆BrN₂O (M+H)⁺: 449.1263, found: 449.1264.




(E)-2,2-diethyl-5-(3-methoxyphenyl)-N-(quinolin-8-yl)pent-4-enamide

¹H NMR (400 MHz, CDCl₃) δ 10.27 (br, 1H), 8.84 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.77 (dd, *J* = 4.0, 1.2 Hz, 1H), 8.14 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.56-7.48 (m, 2H), 7.43 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.16 (t, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 7.6 Hz, 1H), 6.83 (s, 1H), 6.73 (dd, *J* = 8.4, 1.6 Hz, 1H), 6.49 (d, *J* = 15.6 Hz, 1H), 6.24-6.16 (m, 1H), 3.74 (s, 3H), 2.69 (d, *J* = 7.2 Hz, 2H), 1.85 (q, 7.2 Hz, 4H), 0.97 (t, *J* = 7.4 Hz, 6H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.22, 159.87, 148.39, 139.15, 138.98, 136.38, 134.69, 133.11, 129.52, 128.10, 127.59, 126.34, 121.65, 121.36, 118.96, 116.46, 112.81, 111.69, 55.30, 51.53, 37.05, 28.10, 8.71; **HRMS** (EI-TOF) calcd for C₂₅H₂₈N₂O₂ (M⁺): 388.2151, found: 388.2151.



(E)-5-(3-methoxyphenyl)-2,2-dipropyl-N-(quinolin-8-yl)pent-4-enamide


¹H NMR (400 MHz, CDCl₃) δ 10.28 (br, 1H), 8.82 (d, *J* = 7.6 Hz, 1H), 8.78 (d, *J* = 4.0 Hz, 1H), 8.15 (d, *J* = 8.4 Hz, 1H), 7.56-7.42 (m, 3H), 7.18 (t, *J* = 7.6 Hz, 1H), 6.92 (d, *J* = 7.6 Hz, 1H), 6.85 (s, 1H), 6.74 (dd, *J* = 8.0, 1.6 Hz, 1H), 6.48 (d, *J* = 16.0 Hz, 1H), 6.24-6.17 (m, 1H), 3.75 (s, 3H), 2.70 (d, *J* = 7.6 Hz, 2H), 1.78-1.74 (m, 4H), 1.45-1.34 (m, 4H), 0.95 (t, *J* = 7.2 Hz, 6H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.41, 159.87, 148.41, 139.22, 139.00, 136.38, 134.70, 133.13, 129.53, 128.10, 127.59, 126.45, 121.66, 121.35, 118.96, 116.46, 112.71, 111.79, 55.31, 51.07, 38.54, 37.91, 17.60, 14.85; **HRMS** (EI-TOF) calcd for C₂₇H₃₂N₂O₂ (M⁺): 416.2464, found: 416.2468.



(E)-5-(3-methoxyphenyl)-2,2-dimethyl-N-(quinolin-8-yl)pent-4-enamide


¹H NMR (400 MHz, CDCl₃) δ 10.27 (br, 1H), 8.81 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.76 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.15 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.56-7.48 (m, 2H), 7.43 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.26 (s, 1H), 7.15 (t, *J* = 8.0 Hz, 1H), 6.90 (d, *J* = 7.6 Hz, 1H), 6.82 (s, 1H), 6.72 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.47 (d, *J* = 16.0 Hz, 1H), 6.30-6.22 (m, 1H), 3.73 (s, 3H), 2.63 (d, *J* = 7.2 Hz, 2H), 1.46 (s, 6H); **¹³C NMR (100 MHz, CDCl₃)** δ 176.20 (s, 1H), 159.87 (s, 1H), 148.39 (s, 2H), 139.04 (d, *J* = 9.0 Hz, 2H), 136.41 (s, 2H), 134.76 (s, 2H), 133.45 (s, 2H), 129.50 (s, 2H), 128.10 (s, 1H), 127.58 (s, 2H), 126.54 (s, 2H), 121.57 (d, *J* = 19.3 Hz, 4H), 119.04 (s, 2H), 116.50 (s, 2H), 112.94 (s,

2H), 111.67 (s, 2H), 55.30 (s, 2H), 44.59 (s, 2H), 44.32 (s, 1H), 25.60 (s, 4H); **HRMS** (EI-TOF) calcd for $C_{23}H_{24}N_2O_2$ (M^+): 360.1838, found: 360.1837.



(E)-5-(3-methoxyphenyl)-2-((E)-3-(3-methoxyphenyl)allyl)-2-methyl-N-(quinolin-8-yl)pent-4-enamide


^1H NMR (400 MHz, CDCl_3) δ 10.28 (br, 1H), 8.82 (d, J = 7.6 Hz, 1H), 8.69 (dd, J = 4.0, 1.2 Hz, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.56-7.49 (m, 2H), 7.41 (dd, J = 8.0, 4.0 Hz, 1H), 7.15 (t, J = 8.0 Hz, 2H), 6.90 (d, J = 7.6 Hz, 2H), 6.82 (s, 2H), 6.72 (dd, J = 8.4, 2.0 Hz, 2H), 6.49 (d, J = 15.6 Hz, 2H), 6.31-6.23 (m, 2H), 3.72 (s, 6H), 2.69 (ddd, J = 21.6, 14.0, 7.6 Hz, 4H), 1.50 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.98, 159.88, 148.43, 139.02, 136.35, 134.60, 133.73, 129.52, 128.09, 127.54, 126.12, 121.67, 121.59, 119.05, 116.64, 112.99, 111.68, 55.29, 48.13, 43.11, 22.11; **HRMS** (EI-TOF) calcd for $C_{32}H_{32}N_2O_3$ (M^+): 492.2413, found: 492.2414.



(E)-1-(3-(3-methoxyphenyl)allyl)-N-(quinolin-8-yl)cyclopentanecarboxamide


^1H NMR (400 MHz, CDCl_3) δ 10.19 (br, 1H), 8.78 (dd, J = 7.2, 1.2 Hz, 1H), 8.73 (dd, J = 4.0, 1.6 Hz, 1H), 8.14 (dd, J = 8.4, 1.6 Hz, 1H), 7.55-7.47 (m, 2H), 7.42 (dd, J = 8.0, 4.0 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 6.87 (d, J = 7.6 Hz, 1H), 6.78 (s, 1H), 6.70 (dd, J = 8.0, 2.0 Hz, 1H), 6.45 (d, J = 16.0 Hz, 1H), 6.29-6.22 (m, 1H), 3.70 (s, 3H), 2.70 (d, J = 6.8 Hz, 2H), 2.32-2.29 (m, 2H), 1.86-1.74 (m, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 176.05, 159.79, 148.37, 139.04, 138.88, 136.37, 134.85, 133.13, 129.43, 128.07, 127.57, 126.87, 121.63, 121.32, 119.05, 116.40, 112.92, 111.61, 56.21,

55.26, 42.68, 35.84, 24.91; **HRMS** (EI-TOF) calcd for C₂₅H₂₆N₂O₂ (M⁺): 386.1994, found: 386.1996.



(E)-2-benzyl-2-ethyl-5-(3-methoxyphenyl)-N-(quinolin-8-yl)pent-4-enamide


¹H NMR (400 MHz, CDCl₃) δ 10.16 (br, 1H), 8.84 (dd, *J* = 7.2, 0.8 Hz, 1H), 8.68 (dd, *J* = 4.4, 1.6 Hz, 1H), 8.13 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.57-7.48 (m, 2H), 7.40 (dd, *J* = 8.4, 4.0 Hz, 1H), 7.21-7.09 (m, 6H), 6.93 (d, *J* = 7.6 Hz, 1H), 6.85 (s, 1H), 6.75 (dd, *J* = 8.4, 2.0 Hz, 1H), 6.53 (d, *J* = 16.0 Hz, 1H), 6.32-6.25 (m, 1H), 3.75 (s, 3H), 3.16-3.09 (m, 2H), 2.69 (ddd, *J* = 65.2, 14.4, 7.6 Hz, 2H), 1.97-1.90 (m, 1H), 1.85-1.76 (m, 1H), 1.08 (t, *J* = 7.2 Hz, 3H); **¹³C NMR (100 MHz, CDCl₃)** δ 174.51, 159.89, 148.32, 139.11, 138.94, 137.66, 136.30, 134.49, 133.66, 130.32, 129.57, 128.22, 128.04, 127.56, 126.55, 126.02, 121.62, 121.49, 118.98, 116.54, 112.83, 111.78, 55.33, 52.55, 42.13, 37.31, 27.77, 8.85; **HRMS** (EI-TOF) calcd for C₃₀H₃₀N₂O₂ (M⁺): 450.2307, found: 450.2307.



(E)-2-ethyl-2-(3-(3-methoxyphenyl)allyl)-5-methyl-N-(quinolin-8-yl)hexanamide


¹H NMR (400 MHz, CDCl₃) δ 10.28 (br, 1H), 8.82 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.77 (dd, *J* = 4.4, 1.6 Hz, 1H), 8.15 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.56-7.42 (m, 3H), 7.17 (t, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 7.6 Hz, 1H), 6.83 (s, 1H), 6.74 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.49 (d, *J* = 15.6 Hz, 1H), 6.23-6.15 (m, 1H), 3.75 (s, 3H), 2.74-2.64 (m, 2H), 1.87-1.75 (m, 4H), 1.59-1.50 (m, 1H), 1.31-1.21 (m, 2H), 0.97 (t, *J* = 7.2 Hz, 3H), 0.89 (dd, *J* = 6.8, 2.4 Hz, 6H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.32, 159.88,

148.37, 139.21, 139.00, 136.37, 134.72, 133.18, 129.52, 128.11, 127.60, 126.37, 121.65, 121.33, 118.96, 116.46, 112.77, 111.72, 55.29, 51.11, 37.32, 33.48, 33.12, 28.72, 28.52, 22.74, 8.69; **HRMS** (EI-TOF) calcd for C₂₈H₃₄N₂O₂ (M⁺): 430.2620, found: 430.2619.



(E)-2-ethyl-2-(3-(3-methoxyphenyl)allyl)-N-(quinolin-8-yl)hexanamide


¹H NMR (400 MHz, CDCl₃) δ 10.27 (br, 1H), 8.83 (d, *J* = 7.6 Hz, 1H), 8.77 (d, *J* = 2.8 Hz, 1H), 8.15 (d, *J* = 8.0 Hz, 1H), 7.56-7.48 (m, 2H), 7.43 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.17 (t, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 7.6 Hz, 1H), 6.84 (s, 1H), 6.74 (d, *J* = 8.4 Hz, 1H), 6.49 (d, *J* = 15.6 Hz, 1H), 6.26-6.14 (m, 1H), 3.75 (s, 3H), 2.74-2.64 (m, 2H), 1.85 (q, *J* = 7.6 Hz, 2H), 1.77 (t, *J* = 4.4 Hz, 2H), 1.36-1.35 (m, 4H), 0.97 (t, *J* = 7.2 Hz, 3H), 0.89 (t, *J* = 6.8 Hz, 3H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.36, 159.87, 148.39, 139.20, 138.99, 136.38, 134.71, 133.13, 129.53, 128.10, 127.60, 126.39, 121.66, 121.35, 118.96, 116.46, 112.76, 111.73, 55.31, 51.18, 37.39, 35.55, 28.45, 26.42, 23.41, 14.14, 8.70; **HRMS** (EI-TOF) calcd for C₂₇H₃₂N₂O₂ (M⁺): 416.2464, found: 416.2464.



(E)-2-ethyl-2-(3-(3-methoxyphenyl)allyl)-N-(quinolin-8-yl)octanamide


¹H NMR (400 MHz, CDCl₃) δ 10.27 (br, 1H), 8.83 (d, *J* = 7.6 Hz, 1H), 8.77 (d, *J* = 2.8 Hz, 1H), 8.15 (d, *J* = 8.0 Hz, 1H), 7.56-7.48 (m, 2H), 7.44 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.17 (t, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 7.6 Hz, 1H), 6.84 (s, 1H), 6.74 (dd, *J* = 8.4, 2.0 Hz, 1H), 6.49 (d, *J* = 15.6 Hz, 1H), 6.223-6.16 (m, 1H), 3.75 (s, 3H), 2.74-2.64 (m,

2H), 1.85 (q, $J = 7.2$ Hz, 2H), 1.79-1.75 (m, 2H), 1.39-1.25 (m, 8H), 0.97 (t, $J = 7.2$ Hz, 3H), 0.83 (t, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.35, 159.87, 148.38, 139.20, 138.99, 136.38, 134.72, 133.13, 129.52, 128.10, 127.60, 126.42, 121.66, 121.34, 118.96, 116.46, 112.77, 111.72, 55.31, 51.22, 37.39, 35.83, 31.79 (s, 2H), 30.00 (s, 2H), 28.50 (s, 2H), 24.16 (s, 2H), 22.75 (s, 2H), 14.17, 8.72; HRMS (EI-TOF) calcd for $\text{C}_{29}\text{H}_{36}\text{N}_2\text{O}_2$ (M^+): 444.2777, found: 444.2774.



(E)-2-allyl-5-(3-methoxyphenyl)-2-phenyl-N-(quinolin-8-yl)pent-4-enamide


^1H NMR (400 MHz, CDCl_3) δ 9.85 (br, 1H), 8.76 (d, $J = 7.6$ Hz, 1H), 8.58 (dd, $J = 4.0, 1.2$ Hz, 1H), 8.08 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.54-7.28 (m, 8H), 7.14 (t, $J = 7.6$ Hz, 1H), 6.82 (d, $J = 7.6$ Hz, 1H), 6.73-6.71 (m, 2H), 6.42 (d, $J = 15.6$ Hz, 1H), 6.01-5.94 (m, 1H), 5.77-5.66 (m, 1H), 5.17-5.08 (m, 2H), 3.74 (s, 3H), 3.17-2.95 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.79, 159.82, 148.30, 142.24, 139.11, 138.81, 136.19, 134.70, 133.78, 133.60, 129.48, 128.90, 128.01, 127.46, 127.38, 127.33, 125.91, 121.57, 121.42, 119.04, 118.94, 116.30, 112.73, 111.82, 55.56, 55.30, 40.10, 39.23; HRMS (EI-TOF) calcd for $\text{C}_{30}\text{H}_{28}\text{N}_2\text{O}_2$ (M^+): 448.2151, found: 448.2151.



(E)-5-(3-methoxyphenyl)-2-methyl-2-phenyl-N-(quinolin-8-yl)pent-4-enamide


^1H NMR (400 MHz, CDCl_3) δ 9.89 (br, 1H), 8.78 (d, $J = 7.6$ Hz, 1H), 8.58 (dd, $J = 4.0, 1.2$ Hz, 1H), 8.07 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.54-7.29 (m, 8H), 7.14 (t, $J = 8.0$ Hz, 1H), 6.84 (d, $J = 7.6$ Hz, 1H), 6.77 (s, 1H), 6.72 (dd, $J = 8.0, 1.6$ Hz, 1H), 6.44 (d, $J = 15.6$ Hz, 1H), 6.10-6.02 (m, 1H), 3.74 (s, 3H), 3.09 (ddd, $J = 20.8, 14.0, 7.6$ Hz, 2H),

1.80 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.98, 159.85, 148.26, 143.37, 139.12, 138.83, 136.20, 134.78, 133.57, 129.48, 128.94, 127.99, 127.45, 127.29, 126.96, 126.62, 121.57, 121.45, 118.97, 116.23, 112.78, 111.76, 55.31, 52.12, 43.24, 23.71; HRMS (EI-TOF) calcd for $\text{C}_{28}\text{H}_{26}\text{N}_2\text{O}_2$ (M^+): 422.1994, found: 422.1995.



(E)-5-(3-methoxyphenyl)-2-((E)-3-(3-methoxyphenyl)allyl)-2-phenyl-N-(quinolin-8-yl)pent-4-enamide


^1H NMR (400 MHz, CDCl_3) δ 9.91 (br, 1H), 8.78 (dd, $J = 7.6, 1.2$ Hz, 1H), 8.53 (dd, $J = 4.0, 1.6$ Hz, 1H), 8.07 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.54-7.30 (m, 8H), 7.25 (s, 1H), 7.15 (t, $J = 7.6$ Hz, 2H), 6.83 (d, $J = 7.6$ Hz, 2H), 6.75-6.71 (m, 4H), 6.45 (d, $J = 15.6$ Hz, 2H), 6.09-6.02 (m, 2H), 3.74 (s, 6H), 3.14 (ddd, $J = 21.2, 14.4, 7.6$ Hz, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.74, 159.85, 148.31, 142.17, 139.08, 138.82, 136.17, 134.70, 133.93, 129.51, 128.97, 128.01, 127.45, 127.38, 125.84, 121.57, 121.47, 118.98, 116.38, 112.81, 111.83, 55.92, 55.31, 39.68; HRMS (EI-TOF) calcd for $\text{C}_{37}\text{H}_{34}\text{N}_2\text{O}_3$ (M^+): 554.2569, found: 554.2565.



(E)-2-ethyl-5-(3-methoxyphenyl)-2-phenyl-N-(quinolin-8-yl)pent-4-enamide


^1H NMR (400 MHz, CDCl_3) δ 9.84 (br, 1H), 8.78 (d, $J = 7.6$ Hz, 1H), 8.58 (dd, $J = 4.0, 1.2$ Hz, 1H), 8.07 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.53-7.27 (m, 8H), 7.14 (t, $J = 8.0$ Hz, 1H), 6.82 (d, $J = 7.6$ Hz, 1H), 6.74-6.70 (m, 2H), 6.41 (d, $J = 16.0$ Hz, 1H), 5.98-5.90 (m, 1H), 3.74 (s, 3H), 3.10 (ddd, $J = 20.8, 14.4, 7.6$ Hz, 2H), 2.33-2.21 (m, 2H), 0.96 (t, $J = 7.6$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.39, 159.81, 148.29, 142.72,

139.13, 138.79, 136.18, 134.77, 133.18, 129.47, 128.81, 128.00, 127.45, 127.39, 127.21, 126.26, 121.55, 121.33, 118.91, 116.20, 112.70, 111.75, 56.12, 55.30, 38.68, 28.02, 8.78; **HRMS** (EI-TOF) calcd for C₂₉H₂₈N₂O₂ (M⁺): 436.2151, found: 436.2152.



(E)-2-(3-(3-methoxyphenyl)allyl)-2-phenyl-N-(quinolin-8-yl)octanamide


¹H NMR (400 MHz, CDCl₃) δ 9.83 (br, 1H), 8.77 (d, *J* = 7.6 Hz, 1H), 8.58 (d, *J* = 4.0 Hz, 1H), 8.07 (d, *J* = 8.0 Hz, 1H), 7.54-7.26 (m, 8H), 7.14 (t, *J* = 8.0 Hz, 1H), 6.82 (d, *J* = 7.6 Hz, 1H), 6.74-6.71 (m, 2H), 6.39 (d, *J* = 15.6 Hz, 1H), 5.96-5.89 (m, 1H), 3.74 (s, 3H), 3.09 (ddd, *J* = 20.8, 14.4, 7.6 Hz, 2H), 2.20 (t, *J* = 6.8 Hz, 2H), 1.33-1.23 (m, 8H), 0.79 (t, *J* = 6.6 Hz, 3H); **¹³C NMR (100 MHz, CDCl₃)** δ 174.50, 159.81, 148.26, 142.96, 139.21, 138.82, 136.17, 134.80, 133.20, 129.46, 128.80, 128.00, 127.46, 127.33, 127.18, 126.40, 121.55, 121.31, 118.93, 116.22, 112.64, 111.79, 55.78, 55.30, 39.41, 35.29, 31.68, 29.93, 24.09, 22.71, 14.12; **HRMS** (EI-TOF) calcd for C₃₃H₃₆N₂O₂ (M⁺): 492.2777, found: 492.2777.



(E)-2-(3-(3-methoxyphenyl)allyl)-2-phenyl-N-(quinolin-8-yl)hexanamide


¹H NMR (400 MHz, CDCl₃) δ 9.84 (br, 1H), 8.77 (d, *J* = 7.6 Hz, 1H), 8.58 (d, *J* = 4.0 Hz, 1H), 8.07 (d, *J* = 8.0 Hz, 1H), 7.54-7.27 (m, 8H), 7.14 (t, *J* = 8.0 Hz, 1H), 6.82 (d, *J* = 7.6 Hz, 1H), 6.74-6.71 (m, 2H), 6.39 (d, *J* = 16.0 Hz, 1H), 5.97-5.89 (m, 1H), 3.74 (s, 3H), 3.10 (ddd, *J* = 20.8, 14.4, 7.6 Hz, 2H), 2.23-2.19 (m, 2H), 1.40-1.28 (m, 4H), 0.87 (t, *J* = 6.4 Hz, 3H); **¹³C NMR (100 MHz, CDCl₃)** δ 174.50, 159.80,

148.27, 142.94, 139.20, 138.80, 136.17, 134.78, 133.20, 129.47, 128.80, 128.00, 127.45, 127.33, 127.18, 126.36, 121.56, 121.32, 118.92, 116.21, 112.61, 111.80, 55.73, 55.30, 39.38, 35.05, 26.38, 23.37, 14.11; **HRMS** (EI-TOF) calcd for $C_{31}H_{32}N_2O_2$ (M^+): 464.2464, found: 464.2460.



(E)-2-(3-(3-methoxyphenyl)allyl)-5-methyl-2-phenyl-N-(quinolin-8-yl)hexanamide
e


1H NMR (400 MHz, $CDCl_3$) δ 9.83 (br, 1H), 8.77 (dd, $J = 7.6, 0.8$ Hz, 1H), 8.58 (dd, $J = 4.4, 1.6$ Hz, 1H), 8.07 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.54-7.26 (m, 8H), 7.14 (t, $J = 7.6$ Hz, 1H), 6.82 (d, $J = 7.6$ Hz, 1H), 6.74-6.70 (m, 2H), 6.40 (d, $J = 16$ Hz, 1H), 5.96-5.88 (m, 1H), 3.74 (s, 3H), 3.17-3.01 (m, 2H), 2.24-2.20 (m, 2H), 1.57-1.51 (m, 1H), 1.26-1.22 (m, 2H), 0.86 (dd, $J = 6.4, 2.4$ Hz, 6H); **^{13}C NMR (100 MHz, $CDCl_3$)** δ 174.50, 159.80, 148.26, 143.00, 139.21, 138.81, 136.16, 134.79, 133.26, 129.47, 128.80, 128.00, 127.45, 127.29, 127.18, 126.34, 121.56, 121.32, 118.92, 116.22, 112.60, 111.80, 55.60, 55.29, 39.21, 33.06, 32.99, 28.70, 22.74; **HRMS** (EI-TOF) calcd for $C_{32}H_{34}N_2O_2$ (M^+): 478.2620, found: 478.2621.



(E)-2-(3-(3-methoxyphenyl)allyl)-2-phenyl-N-(quinolin-8-yl)tetradecanamide

1H NMR (400 MHz, $CDCl_3$) δ 9.83 (br, 1H), 8.77 (d, $J = 7.6$ Hz, 1H), 8.58 (d, $J = 2.4$ Hz, 1H), 8.07 (d, $J = 8.0$ Hz, 1H), 7.54-7.26 (m, 8H), 7.14 (t, $J = 8.0$ Hz, 1H), 6.82 (d, $J = 7.6$ Hz, 1H), 6.74-6.71 (m, 2H), 6.39 (d, $J = 16.0$ Hz, 1H), 5.96-5.89 (m, 1H), 3.74 (s, 3H), 3.09 (ddd, $J = 20.4, 14.4, 7.6$ Hz, 2H), 2.20 (t, $J = 7.5$ Hz, 2H),


1.32-1.16 (m, 20H), 0.87 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.50, 159.82, 148.26, 142.97, 139.21, 138.82, 136.16, 134.80, 133.20, 129.46, 128.80, 128.01, 127.46, 127.33, 127.18, 126.40, 121.54, 121.31, 118.93, 116.22, 112.63, 111.80, 55.78, 55.29, 39.40, 35.25, 32.05, 30.24, 29.76, 29.73, 29.69, 29.46, 24.09, 22.82, 14.25; **HRMS** (ESI-TOF) calcd for $\text{C}_{39}\text{H}_{48}\text{N}_2\text{O}_2$ (M^+): 576.3716, found: 576.3714.



(E)-5-(3-methoxyphenyl)-2-methyl-2-(4-methylbenzyl)-N-(quinolin-8-yl)pent-4-enamide

^1H NMR (400 MHz, CDCl_3) δ 10.12 (br, 1H), 8.84 (d, $J = 7.6$ Hz, 1H), 8.66 (dd, $J = 4.0, 1.6$ Hz, 1H), 8.10 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.56-7.46 (m, 2H), 7.37 (dd, $J = 8.0, 4.0$ Hz, 1H), 7.14-7.08 (m, 3H), 6.98 (d, $J = 7.6$ Hz, 2H), 6.87 (d, $J = 7.2$ Hz, 1H), 6.79 (s, 1H), 6.70 (dd, $J = 8.0, 2.0$ Hz, 1H), 6.47 (d, $J = 15.6$ Hz, 1H), 6.29-6.22 (m, 1H), 3.68 (s, 3H), 3.26 (d, $J = 13.2$ Hz, 1H), 2.93-2.85 (m, 2H), 2.43 (dd, $J = 13.6, 8.4$ Hz, 1H), 2.22 (s, 3H), 1.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.95, 159.80, 148.27, 139.03, 138.92, 136.26, 136.03, 134.52, 133.61, 130.33, 129.46, 128.87, 128.00, 127.51, 126.31, 121.57, 121.51, 119.00, 116.52, 112.90, 111.60, 55.22, 49.02, 45.76, 43.39, 21.14, 21.09; **HRMS** (EI-TOF) calcd for $\text{C}_{30}\text{H}_{30}\text{N}_2\text{O}_2$ (M^+): 450.2307, found: 450.2305.

2.3 Sequential C(sp³)-H Bonds Functionalizaion of Product



Synthesis of compound **5**^[1]

To an oven-dried 50 mL screw-capped vial was added substrate **1d** (5.0 mmol, 1.0 eq.), aryl iodide (7.5 mmol, 1.5 eq.), Ni(OTf)₂ (0.25 mmol, 0.05 eq.), MesCOOH (0.5 mmol, 0.1 eq.), Na₂CO₃ (10.0 mmol, 2.0 eq.), in DMF (10 mL). The mixture was stirred for 24 h at 160 °C under N₂ followed by cooling. The resulting mixture was added water (10 mL), then extracted with EtOAc (20 mL) for three times. The combined organic phase washed with brine (20 mL) for three times and concentrated *in vacuo*. The residue was purified by flash chromatography using hexane/EtOAc as the eluent to afford the product. **¹H NMR (400 MHz, CDCl₃)** δ 10.16 (br, 1H), 8.82 (dd, *J* = 7.6, 1.6 Hz, 1H), 8.75 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.14 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.57-7.48 (m, 2H), 7.43 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.07 (d, *J* = 8.0 Hz, 2H), 6.99 (d, *J* = 8.0 Hz, 2H), 3.00 (s, 2H), 2.24 (s, 3H), 1.40 (s, 6H); **¹³C NMR (100 MHz, CDCl₃)** δ 176.28, 148.24, 138.92, 136.33, 135.91, 134.91, 134.68, 130.26, 128.80, 128.01, 127.55, 121.59, 121.41, 116.40, 46.60, 45.07, 25.34, 21.08; **HRMS (EI-TOF)** calcd for C₂₁H₂₂N₂O₂ (M⁺): 318.1732, found: 318.1730.

Synthesis of compound **6**


To an oven-dried 50 mL screw-capped vial was added substrate **10** (0.1 mmol, 1.0 eq.), HCO₂NH₄ (1.0 mmol, 10.0 eq.), Pd/C (0.01 mmol, 0.1 eq.), in MeOH (1.0 mL). The mixture was stirred for 8 h at 80 °C under air followed by cooling. The resulting mixture was filtered through a celite pad and concentrated in *vacuo*. The residue was purified by preparative TLC using hexane/EtOAc as the eluent to afford the product **6**. **¹H NMR (400 MHz, CDCl₃)** δ 10.10 (br, 1H), 8.83 (d, *J* = 7.6 Hz, 1H), 8.71 (d, *J* = 2.8 Hz, 1H), 8.11 (d, *J* = 7.2 Hz, 1H), 7.55-7.46 (m, 2H), 7.39 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.12 (t, *J* = 7.6 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 2H), 6.96 (d, *J* = 8.0 Hz, 2H), 6.73 (d, *J* = 7.2 Hz, 1H), 6.67 (d, *J* = 7.6 Hz, 2H), 3.70 (s, 3H), 3.19 (d, *J* = 13.2 Hz, 1H), 2.78 (d, *J* = 13.2 Hz, 1H), 2.68-2.54 (m, 2H), 2.21 (s, 3H), 2.03 (td, *J* = 12.4, 3.6 Hz, 1H), 1.77-1.69 (m, 2H), 1.58 (td, *J* = 12.4, 3.6 Hz, 1H), 1.34 (s, 3H); **¹³C NMR (100 MHz, CDCl₃)** δ 175.37, 159.65, 148.26, 143.96, 138.88, 136.30, 135.89, 134.64, 134.53, 130.28, 129.30, 128.79, 127.99, 127.52, 121.58, 121.41, 120.95, 116.36, 114.16, 111.20, 55.15, 48.63, 45.97, 39.85, 36.54, 26.71, 21.09, 20.86; **HRMS** (EI-TOF) calcd for C₃₀H₃₂N₂O₂ (M⁺): 452.2464, found: 452.2467.

Synthesis of compound 7

To an oven-dried 50 mL screw-capped vial was added substrate **6** (0.1 mmol, 1.0 eq.), **2a** (0.2 mmol, 2.0 eq.), Ni(acac)₂ (0.002 mmol, 0.1 eq.), Li₂CO₃ (0.2 mmol, 2.0 eq.), potassium trifluoroacetate (0.2 mmol, 2.0 eq.), in DMSO (1.0 mL). The mixture was stirred for 10 h at 140 °C under N₂ followed by cooling. The resulting mixture was added water (3 mL), then extracted with EtOAc (10 mL) for three times. The combined organic phase washed with brine (10 mL) for three times and concentrated in *vacuo*. The residue was purified by preparative TLC using hexane/EtOAc = 20:1 as the eluent to afford the product **7**. **¹H NMR (400 MHz, CDCl₃)** δ 10.14 (br, 1H), 8.81 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.67 (dd, *J* = 4.0, 1.2 Hz, 1H), 8.14 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.57-7.39 (m, 2H), 7.41 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.18 (t, *J* = 8.0 Hz, 1H), 7.12 (t, *J* = 8.0 Hz, 1H), 7.02 (d, *J* = 8.0 Hz, 2H), 6.94 (d, *J* = 8.0 Hz, 2H), 6.89 (d, *J* = 7.6 Hz, 1H), 6.81 (s, 1H), 6.76-6.66 (m, 4H), 6.49 (d, *J* = 15.6 Hz, 1H), 6.25-6.18 (m, 1H), 3.76 (s, 3H), 3.69 (s, 3H), 3.06 (q, *J* = 13.6 Hz, 2H), 2.76-2.56 (m, 4H), 2.21 (s, 3H),

1.89-1.74 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.47, 159.86, 159.70, 148.31, 143.81, 139.08, 138.92, 136.29, 136.05, 134.47, 134.29, 133.70, 130.13, 129.54, 129.38, 128.95, 128.03, 127.56, 125.96, 121.62, 121.47, 120.99, 118.95, 116.52, 114.28, 112.75, 111.86, 111.26, 55.33, 55.16, 52.14, 42.03, 37.52, 36.40, 35.00, 26.09, 21.10; HRMS (EI-TOF) calcd for $\text{C}_{39}\text{H}_{40}\text{N}_2\text{O}_3$ (M^+): 584.3039, found: 584.3041.

2.4 Transformation of Product



Synthesis of compound 8

To an oven-dried 50 mL screw-capped vial was added substrate **4k** (0.1 mmol, 1.0 eq.), NMO (1.5 mmol, 1.5 eq.), OsO_4 (0.01 mmol, 0.1 eq.), in Acetone/ H_2O = 1.0 mL/0.2 mL. The mixture was stirred for 1.5 h at rt under air. The resulting mixture was added water (10 mL), then extracted with EtOAc (10 mL) for three times. The combined organic phase washed with brine (10 mL) for three times and concentrated in *vacuo*. The residue was purified by preparative TLC using hexane/EtOAc as the eluent to afford the product **8**. ^1H NMR (400 MHz, CDCl_3) δ 10.01 (br, 0.5H), 9.79 (s, 0.5H), 8.78 (d, J = 7.2 Hz, 0.5 H) 8.76 (d, J = 7.2 Hz, 0.5 H), 8.59 (dd, J = 4.4, 0.8 Hz, 0.5H), 8.54 (dd, J = 4.4, 0.8 Hz, 0.5H), 8.12 (d, J = 8.4 Hz, 0.5H), 8.07 (d, J = 8.4 Hz, 0.5H), 7.58-7.44 (m, 2H), 7.39-7.24 (m, 5H), 7.20-7.10 (m, 2H), 6.87-6.69 (m, 3H), 4.67 (d, J = 2.4 Hz, 1H), 4.45 (d, J = 6.0 Hz, 0.5H), 4.36 (d, J = 6.0 Hz, 0.5H), 3.77 (t, J = 8.8 Hz, 0.5H), 3.75 (s, 1.5H), 3.69 (s, 1.5H), 3.68 (s, 0.5H), 3.47 (t, J = 7.6 Hz, 1H), 3.31 (br, 0.5H), 3.19 (br, 0.5H), 2.54-2.17 (m, 3H), 2.11 (d, J = 14.8 Hz, 0.5H), 2.11 (d, J = 14.8 Hz, 0.5H), 1.75 (d, J = 14.8 Hz, 1H), 1.19-1.15 (m, 1H),

0.92 (dt, $J = 7.6$ Hz, 1.5H), 0.73 (dt, $J = 7.6$ Hz, 1.5H); ^{13}C NMR (100 MHz, CDCl_3) δ 176.20, 175.91, 159.83, 159.68, 148.50, 148.34, 142.61, 142.51, 142.41, 142.29, 138.89, 138.81, 136.32, 136.25, 134.40, 134.16, 129.54, 129.28, 128.92, 128.79, 128.70, 128.06, 128.00, 127.41, 127.36, 127.24, 122.05, 121.79, 121.74, 121.60, 119.98, 119.71, 116.85, 116.65, 114.01, 113.95, 112.24, 112.19, 78.54, 78.22, 72.67, 72.40, 56.97, 55.30, 55.20, 55.01, 40.52, 37.88, 33.29, 28.11, 18.81, 18.79, 9.13, 8.70; HRMS (ESI-TOF) calcd for $\text{C}_{29}\text{H}_{31}\text{N}_2\text{O}_4$ ($\text{M}+\text{H}$) $^+$: 471.2278, found: 471.2295.

Synthesis of compound 9

To an oven-dried 50 mL screw-capped vial was added substrate **4k** (0.1 mmol, 1.0 eq.), HCO_2NH_4 (1.0 mmol, 10.0 eq.), Pd/C (0.01 mmol, 0.1 eq.), in MeOH (1.0 mL). The mixture was stirred for 8 h at 80 °C under air followed by cooling. The resulting mixture was filtered through a celite pad and concentrated in *vacuo*. The residue was purified by preparative TLC using hexane/EtOAc as the eluent to afford the product **9**. ^1H NMR (400 MHz, CDCl_3) δ 9.79 (br, 1H), 8.75 (dd, $J = 7.6$, 1.2 Hz, 1H), 8.58 (dd, $J = 4.0$, 1.6 Hz, 1H), 8.07 (dd, $J = 8.0$, 1.2 Hz, 1H), 7.50 (t, $J = 7.8$ Hz, 1H), 7.44-7.41 (m, 3H), 7.36-7.32 (m, 3H), 7.26-7.23 (m, 2H), 7.12-7.08 (m, 1H), 6.70 (d, $J = 7.2$ Hz, 1H), 6.65-6.64 (m, 2H), 3.71 (s, 3H), 2.62 (t, $J = 6.4$ Hz, 2H), 2.31-2.14 (m, 4H), 1.62-1.46 (m, 2H), 0.81 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.94, 159.68, 148.25, 143.88, 143.17, 138.80, 136.16, 134.84, 129.28, 128.70, 127.99, 127.46, 127.31, 126.98, 121.53, 121.22, 120.97, 116.09, 114.17, 111.22, 55.79, 55.20, 36.44, 34.00, 27.87, 25.67, 8.66; HRMS (ESI-TOF) calcd for $\text{C}_{29}\text{H}_{31}\text{N}_2\text{O}_2$ (M^+): 439.2380, found: 439.2377.

3. Reference

1. Y. Aihara, N. Chatani, *J. Am. Chem. Soc.* 2014, **136**, 898.

4. NMR Spectra

